MedTrace Logo

Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR

NCT00938613 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2012-10-04

No results posted yet for this study

Summary

The primary objective of this study was to compare the relative efficacy of Budesonide administered via Captisol-Enabled Budesonide nasal solution and Rhinocort Aqua in patients with seasonal allergic rhinitis (SAR) exposed to controlled ragweed pollen using an EEC model.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

Budesonide

nasal spray, one spray per nostril at time 0

DRUG

Placebo

nasal spray, one spray per nostril at time 0

DRUG

Budesonide

nasal spray, one spray per nostril at time 0

Sponsors & Collaborators

  • Ligand Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Deepen Patel, MD · Allied Research International - Cetero Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00938613 on ClinicalTrials.gov